MAXIMIZE the potential of targeted protein degradation
Targeted protein degradation (TPD) is a powerful therapeutic modality to eliminate disease-causing proteins that have, thus far, been inadequately addressed or deemed "undruggable" by conventional methods. Degrader molecules exploit cellular degradation pathways to target and remove these proteins. Unlike traditional small molecule inhibitors, they do not rely on the active binding sites of target proteins, thereby opening up a therapeutic space previously considered inaccessible. However, the lack of rational and systematic strategies for identifying and designing target-specific degrader molecules poses a significant challenge for conventional drug discovery methods and has limited the full realization of the potential offered by targeted protein degradation.
NEOsphere Biotechnologies' proteomic degrader drug discovery platform offers a unique approach to systematically link degrader compounds with their entire target landscape. It delivers exceptional coverage and sensitivity, precise quantification, and rapid turnaround times - all designed to accelerate target identification, compound optimization, library expansion, and informed decision-making throughout the drug discovery process.
More Information in our Company Brochure
 |
DISCOVERIdentify high-value novel degrader targets on a large scale |
|
SCREENPerform high-throughput proteomic screening of entire compound libraries with unmatched data quality and completeness |
|
EVALUATEAssess your compounds’ on- and off-target selectivity, potency, and efficacy across the proteome |
|
VERIFYValidate degrader targets through industry-leading global ubiquitinomics |
|
VISUALIZELeverage the neoVERSE data analysis suite to instantly transform large-scale proteomics data into actionable insights for accelerated drug dicovery decisions |
NEOsphere Biotechnologies‘ E3 ligase and target-agnostic platform enables high-throughput, in-depth characterization and optimization of degrader compounds
